McIntosh/Shays hearing on FDA device program slated for June 29.
This article was originally published in The Gray Sheet
Executive SummaryMCINTOSH/SHAYS HEARING ON FDA DEVICE PROGRAM SLATED FOR JUNE 29, according to staffers. Both Congressmen serve on the House Government Reform and Oversight Committee, with Rep. David McIntosh (R-Ind.) chairing the National Economic Growth Subcommittee, and Rep. Christopher Shays (R-Conn.) heading up the Human Resources Subcommittee. Specific elements of the device program to be examined at the joint subcommittee hearing have not yet been determined, staffers say, and witnesses have not yet been scheduled.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.